Clinical Trials Browser

Withdrawn × INDUSTRY × Doxorubicin × Clear all

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04974996 2022-03-29

LOTIS-8

Phase 1 Withdrawn

Lymphoma, Large B-Cell, Diffuse

NCT03059615 2020-07-31

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute